GlassScriptPhysician profile
Andrew C Brown
NPI 1174595987
$4,924.15
in general payments reported to CMS, 2019-2025
26 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $231 · 2021: $470 · 2022: $731 · 2023: $453 · 2024: $1,372 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.65 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $987.56 | 2019-2025 | Rocklatan, Eysuvis, Rhopressa |
| Allergan, INC. | $626.75 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $593.84 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $544.72 | 2024-2025 | Xdemvy |
| Abbvie INC. | $413.85 | 2022-2025 | Durysta, Lumigan |
| Glaukos Corporation | $171.93 | 2024 | Idose |
| Rxsight INC | $169.36 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Ivantis, INC | $128.85 | 2019 | |
| Kala Pharmaceuticals, INC. | $127.17 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.76 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $121.55 | 2022 | |
| Harrow Eye, LLC | $120.20 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $113.66 | 2022-2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $110.92 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $110.41 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $104.83 | 2022-2025 | |
| Ocular Therapeutix, INC. | $93.03 | 2024-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $60.54 | 2023-2024 | Tecnis Simplicity, Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $54.63 | 2019-2021 | |
| Shire North American Group INC | $43.09 | 2019 | |
| Alydia Health | $22.76 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Mallinckrodt Hospital Products INC. | $18.24 | 2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $17.30 | 2019 | |
| Horizon Therapeutics Plc | $13.56 | 2023 | Tepezza |
| Omeros Corporation | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.